Andere talen Nippon Shinyaku Co., Ltd.

Aandelen

4516

JP3717600005

Vertraagde tijd Japan Exchange Andere beurzen 08:00:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4.364 ^JPY	+0,67%		+1,77%	-12,65%

10/04	NIPPON SHINYAKU CO., LTD. : Jefferies & Co. handhaaft koopadvies	ZM
09/02	Vicore Pharma tekent licentieovereenkomst voor kandidaat-geneesmiddel voor idiopathische longfibrose	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Nippon Shinyaku : Submitted Additional Application of Uptravi® tablets 0.2 mg and 0.4 mg for the Treatment of Pediatric PAH and NDA of Pediatric 0.05 mg formulation to MHLW	16/04
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases	05/04
Nippon Shinyaku : Announcement of Research Alliance with MiNA Therapeutics in the Field of Central Nervous System	04/04
Nippon Shinyaku : UCB Japan Obtained Additional Application of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Japan	26/03
Nippon Shinyaku : Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk AML in Japan	26/03
Nippon Shinyaku : Announcement of Alliance Agreement for Pirtobrutinib, a Reversible Non-Covalent BTK Inhibitor in Japan	25/03
Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100	18/03
VILTEPSO® (viltolarsen) injection: Phase II trial (Galactic53 trial) Data presented at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference	06/03
Year-end report 2023	28/02
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate	09/02
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan	09/02
Nippon Shinyaku : The European Commission Grants Orphan Drug Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy	21/12
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (2Q FY2023)(Script+Q&A(Summary))P	07/12
Capricor Therapeutics Announces $23 Million Registered Direct Offering	02-10-23
The Menarini Group Announces ELZONRIS Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare	31-08-23
Nippon Shinyaku Co., Ltd. Provides Earnings Guidance for the Fiscal Year 2023	10-08-23
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (1Q FY2023	10-08-23
Nippon Shinyaku : Outline of Consolidated Financial Results for the First Quarter Ende	10-08-23
Nippon Shinyaku : Notice Of Resolutions Of The 160th Annual General Meeting of Shareholders	29-06-23
Nippon Shinyaku : Submission of New Drug Application for NS-87 (daunorubicin and cytarabine liposome injection) in Japan	21-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Nippon Shinyaku Co., Ltd.

Aandelen

4516

JP3717600005

Andere talen

Filters